For example, MLL-rearranged leukemias with PRC2 loss, either pre-existing or acquired, are resistant to BRDi presumably due to enhanced transcription of oncogenes such as MYC (129); furthermore, recent reports documented acquisition of somatic mutation by blood cancer cells during resistance to BRDi or EZHi (129, 130). This evidence concerns the gene KMT2A and hematopoietic and lymphoid system neoplasm.